Profile data is unavailable for this security.
About the company
Genscript Biotech Corp is an investment holding company principally engaged in the manufacture and sale of life science research products and services. The Company operates its businesses through five segments. The Life-science Services and Products segment provides comprehensive research services and products. The Biologics Development Services segment provides comprehensive services to help biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene, cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment provides industrial enzyme development and production through non-pathogenic microbial strains constructed using genetic engineering. The Cell Therapy segment discovers and develops CAR-T therapies for the treatment of liquid and solid tumors. The Operation segment provides shared services to other segments. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in HKD (TTM)4.31bn
- Net income in HKD644.58m
- Incorporated2015
- Employees5.77k
- LocationGenscript Biotech CorpNo. 28Yongxi Road, Jiangning Science ParkNANJING ChinaCHN
- Phone+86 2 558897288
- Fax+86 2 558897288
- Websitehttps://www.genscript.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Keymed Biosciences Inc | 987.84m | -291.46m | 16.30bn | 1.47k | -- | 4.50 | -- | 16.50 | -1.11 | -1.11 | 3.75 | 12.11 | 0.2068 | 0.3382 | 15.10 | 785,244.60 | -6.10 | -40.63 | -7.27 | -44.60 | 95.19 | -- | -29.48 | -593.20 | 3.74 | -- | 0.2145 | -- | 20.91 | -- | -43.38 | -- | 28.05 | -- |
| Ascentage Pharma Group International | 442.39m | -1.31bn | 17.73bn | 605.00 | -- | 21.98 | -- | 40.08 | -4.02 | -4.02 | 1.35 | 2.16 | 0.1270 | 3.70 | 0.9505 | 780,234.30 | -37.68 | -30.84 | -60.56 | -41.94 | 90.87 | 94.02 | -296.81 | -252.93 | 1.53 | -- | 0.7174 | -- | 341.77 | 132.25 | 56.20 | -- | -21.49 | -- |
| Genscript Biotech Corp | 4.31bn | 644.58m | 26.33bn | 5.77k | 39.55 | 0.7597 | 44.96 | 6.10 | 0.3044 | 11.44 | 2.02 | 15.85 | 0.1259 | 5.94 | 4.39 | 774,704.90 | 0.3949 | -9.75 | 0.4933 | -13.19 | 51.78 | 52.05 | 3.14 | -46.54 | 1.90 | 1.18 | 0.0471 | -- | 6.07 | 16.81 | -115.90 | -- | 5.78 | -- |
| TransThera Sciences (Nanjing) Inc | 0.00 | -268.52m | 27.43bn | 121.00 | -- | 41.38 | -- | -- | -0.6766 | -0.6766 | 0.00 | 1.66 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.89 | -- | 0.0052 | -- | -100.00 | -- | 20.03 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 07 Jan 2026 | 46.22m | 2.11% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 26.97m | 1.23% |
| BlackRock Fund Advisorsas of 09 Jan 2026 | 25.90m | 1.19% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 22.57m | 1.03% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 18.99m | 0.87% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 16.18m | 0.74% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 15.46m | 0.71% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 15.29m | 0.70% |
| HuaAn Fund Management Co., Ltd.as of 30 Jun 2025 | 13.98m | 0.64% |
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2025 | 12.69m | 0.58% |
